These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37401314)

  • 41. Achievement of national clinical practice recommendations among those in the Puerto Rican population with diabetes mellitus.
    Rodríguez-Vigil E; Rodríguez-Chacón M; Trabanco C; Irizarry-Ramos J
    P R Health Sci J; 2014 Dec; 33(4):157-62. PubMed ID: 25563032
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improvement of glycemic control by 1 year of insulin therapy leads to a sustained decrease in sE-selectin concentrations in type 2 diabetes.
    Ryysy L; Yki-Järvinen H
    Diabetes Care; 2001 Mar; 24(3):549-54. PubMed ID: 11289483
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.
    Singhal M; Unni S; Schauerhamer M; Nguyen H; Hurd J; McAdam-Marx C
    J Manag Care Spec Pharm; 2017 Mar; 23(3):267-275. PubMed ID: 28230449
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glycemic control and associated factors among type 2 diabetes mellitus patients: a cross-sectional study of Azar cohort population.
    Dinavari MF; Sanaie S; Rasouli K; Faramarzi E; Molani-Gol R
    BMC Endocr Disord; 2023 Dec; 23(1):273. PubMed ID: 38087260
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with type 2 diabetes independent of diabetic control.
    Bavirti S; Ghanaat F; Tayek JA
    Endocr Pract; 2003; 9(6):487-93. PubMed ID: 14715475
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: A cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank.
    Jiang G; Luk AO; Tam CHT; Lau ES; Ozaki R; Chow EYK; Kong APS; Lim CKP; Lee KF; Siu SC; Hui G; Tsang CC; Lau KP; Leung JYY; Tsang MW; Kam G; Lau IT; Li JK; Yeung VT; Lau E; Lo S; Fung SKS; Cheng YL; Chow CC; Pearson ER; So WY; Chan JCN; Ma RCW; ;
    PLoS Med; 2020 Jul; 17(7):e1003209. PubMed ID: 32722720
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Control and complications of diabetes in urban primary care units in Thailand: a cross-sectional study.
    Puangpet T; Pongkunakorn T; Chulkarat N; Bunlangjit C; Surawit A; Pinsawas B; Mongkolsucharitkul P; Mayurasakorn K
    BMC Prim Care; 2022 Aug; 23(1):212. PubMed ID: 35996081
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of glycemic control and related factors among outpatients with type 2 diabetes at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: a cross-sectional study.
    Abera RG; Demesse ES; Boko WD
    BMC Endocr Disord; 2022 Mar; 22(1):54. PubMed ID: 35249547
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of depression and parasympathetic activation with glycemic control in type 2 diabetes mellitus.
    Lin KD; Chang LH; Wu YR; Hsu WH; Kuo CH; Tsai JR; Yu ML; Su WS; Lin IM
    J Diabetes Complications; 2022 Aug; 36(8):108264. PubMed ID: 35842305
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glycemic control in Kuwaiti diabetes patients treated with glucose-lowering medication.
    Abdullah A; Alkandari A; Longenecker JC; Devarajan S; Alkhatib A; Al-Wotayan R; Al-Duwairi Q; Tuomilehto J
    Prim Care Diabetes; 2020 Aug; 14(4):311-316. PubMed ID: 31911041
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.
    Risovic I; Dumanovic MS; Bojic M; Djekic D
    BMC Endocr Disord; 2023 Feb; 23(1):28. PubMed ID: 36726134
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus: effect of glycemic control.
    Pérez A; Wägner AM; Carreras G; Giménez G; Sánchez-Quesada JL; Rigla M; Gómez-Gerique JA; Pou JM; de Leiva A
    Arch Intern Med; 2000 Oct; 160(18):2756-62. PubMed ID: 11025785
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus.
    Gutierrez MJ; Rosenberg NL; Macdougall DE; Hanselman JC; Margulies JR; Strange P; Milad MA; McBride SJ; Newton RS
    Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):676-83. PubMed ID: 24385236
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Beneficial effects of green cardamom on serum SIRT1, glycemic indices and triglyceride levels in patients with type 2 diabetes mellitus: a randomized double-blind placebo controlled clinical trial.
    Aghasi M; Koohdani F; Qorbani M; Nasli-Esfahani E; Ghazi-Zahedi S; Khoshamal H; Keshavarz A; Sotoudeh G
    J Sci Food Agric; 2019 Jun; 99(8):3933-3940. PubMed ID: 30701554
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of whey protein on glycemic control and serum lipoproteins in patients with metabolic syndrome and related conditions: a systematic review and meta-analysis of randomized controlled clinical trials.
    Amirani E; Milajerdi A; Reiner Ž; Mirzaei H; Mansournia MA; Asemi Z
    Lipids Health Dis; 2020 Sep; 19(1):209. PubMed ID: 32958070
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lipid and lipoprotein patterns in type 2 non-obese diabetic patients. Do Lp(a) levels decrease with improved glycemic control in these patients?
    Alagözlü H; Gültekin F; Candan F
    Nutr Metab Cardiovasc Dis; 2000 Aug; 10(4):204-8. PubMed ID: 11079258
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus.
    Göke B;
    Treat Endocrinol; 2002; 1(5):329-36. PubMed ID: 15832486
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Poor glycemic control and associated factors among pediatric diabetes mellitus patients in northwest Ethiopia, 2020: facility-based cross sectional retrospective study design.
    Kidie AA; Ayal BG; Ayele T; Fentie EA; Lakew AM
    Sci Rep; 2022 Sep; 12(1):15664. PubMed ID: 36123389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.